Clinical Outcomes of Noninhibitor Patients with Hemophilia a Switching from Prophylaxis with Factor VIII to Emicizumab: A Meta-Analysis of Real-World Evidence Studies

被引：0
|
作者：
Escobar, Miguel A. [1 ]
Fan, Qi Angela [2 ]
Mokdad, Ali G. [3 ]
Tarantino, Michael D. [4 ]
Burgess, Benjamin [5 ]
Hawe, Emma [5 ]
Fernandez, Maria [6 ]
Bullano, Michael [2 ]
机构：
[1] Univ Texas Hlth Sci Ctr Houston, Div Hematol & Oncol, Dept Med, Houston, TX USA
[2] Takeda Pharmaceut Inc, Lexington, MA USA
[3] Takeda Pharmaceut, Cambridge, MA USA
[4] Univ Illinois, Coll Med, Bleeding & Clotting Disorders Inst, Peoria, IL USA
[5] RTI Hlth Solut, Manchester, Lancs, England
[6] RTI Hlth Solut, Res Triangle Pk, NC USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-178007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Methods for the inclusion of real-world evidence in network meta-analysis
    David A. Jenkins
    Humaira Hussein
    Reynaldo Martina
    Pascale Dequen-O’Byrne
    Keith R. Abrams
    Sylwia Bujkiewicz
    BMC Medical Research Methodology, 21
  • [22] Methods for the inclusion of real-world evidence in network meta-analysis
    Jenkins, David A.
    Hussein, Humaira
    Martina, Reynaldo
    Dequen-O'Byrne, Pascale
    Abrams, Keith R.
    Bujkiewicz, Sylwia
    BMC MEDICAL RESEARCH METHODOLOGY, 2021, 21 (01)
  • [23] Real-world data about Bleeding outcomes and joint health of paediatric severe haemophilia A patients on emicizumab prophylaxis
    Hassan, Eman
    Motwani, Jayashree
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 30 - 30
  • [24] A Real-World Study of Pre- Post Annualized Bleed Rates and All Cause Costs Among Non-Inhibitor Patients with Hemophilia a Switching from FVIII Prophylaxis to Emicizumab
    Batt, Katharine
    Schultz, Bob G.
    Caicedo, Jorge
    Hollenbeak, Christopher S.
    Agrawal, Neha
    Chatterjee, Sagnik
    Dayma, Megha
    Bullano, Michael
    BLOOD, 2021, 138
  • [25] Real-world persistence with and adherence to Emicizumab Prophylaxis in People with Hemophilia A- Results from two secondary claims database analyses
    Khairnar, Rahul
    Meyer, Craig
    Schuldt, Robert
    Yang, Baiyu
    Tzeng, Eunice
    Lee, Lucy
    Mahajerin, Arash
    HAEMOPHILIA, 2022, 28 : 70 - 70
  • [26] Antipsychotic therapy: from meta-analysis experience to real-world clinical practice
    A Vidalis
    Annals of General Hospital Psychiatry, 2 (Suppl 1):
  • [27] Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada
    Sun, Haowei Linda
    Yang, Ming
    Poon, Man-Chiu
    Lee, Adrienne
    Robinson, Katherine Sue
    Sholzberg, Michelle
    Wu, John K.
    Iorio, Alfonso
    Blanchette, Victor S.
    Klaassen, Robert J.
    Jackson, Shannon
    BLOOD, 2018, 132
  • [28] Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study
    Pipe, Steven
    Collins, Peter
    Dhalluin, Christophe
    Kenet, Gili
    Schmitt, Christophe
    Buri, Muriel
    Jimenez-Yuste, Victor
    Peyvandi, Flora
    Young, Guy
    Oldenburg, Johannes
    Mancuso, Maria Elisa
    Kavakli, Kaan
    Kiialainen, Anna
    Chang, Tiffany
    Lehle, Michaela
    Niggli, Markus
    Fijnvandraat, Karin
    BLOOD, 2023, 142
  • [29] Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    ENDOCRINE REVIEWS, 2021, 42 (05) : 658 - 690
  • [30] CONVALESCENT plasma for COVID-19: A meta-analysis of clinical trials and real-world evidence
    Kloypan, Chiraphat
    Saesong, Matthanaporn
    Sangsuemoon, Juthamat
    Chantharit, Prawat
    Mongkhon, Pajaree
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 (11)
12345